目的评价Topotecan联合顺铂方案治疗非小细胞肺癌脑转移的临床疗效。方法对32例非小细胞肺癌伴脑转移的患者用Topotecan联合顺铂方案进行化疗,观察患者脑部及胸部CT的改变以确定该方案的疗效及毒性反应。结果Topotecan联合顺铂方案治疗组中,脑部病灶客观有效率53.1%,肺部病灶的有效率为56.3%,两者间差异无统计学意义(P>0.05)。结论Topotecan联合顺铂方案是一种有效的治疗非小细胞肺癌脑转移的化疗方案。
原发性支气管肺癌脑转移的发生率高达20%~50%,预后较差,死亡率较高,自然生存期为3个月,放疗为主要的治疗手段,可延长生存期3~6个月[1]。单发的脑转移适合手术治疗,但多数患者存在多发的、不可切除的脑转移灶,并常常同时伴随全身性疾病,其预后差。因此,有必要探索新的治疗模式来提高疗效。但长期以来,由于受“血脑屏障限制了大多数化疗药进入中枢神经系统”这一观点的影响,全身化疗一直不被认为是一种有效的治疗脑转移的手段。随着抗肿瘤药物研究的深入和联合应用,化疗已成为治疗晚期非小细胞肺癌的重要手段,因顾及血脑屏障的影响,化疗在肺癌…
Objective To evaluate the clinical efficacy of Topotecan/DDP regimen to treat brain metastasis with non-small cell lung cancer.Methods From March 2003 to January 2007,32 previously untreated patients with brain metastasis of non-small cell lung cancer were treated by Topotecan/DDP regimen.Results The Topotecan/DDP treatment achieved a significant proportion of response rate from brain CT scan.Then there was no significant difference of response rate between brain and chest(P>0.05).Conclusions The Topotecan/DDP is a valid chemotherapy regimen to treat brain metastasis patients with non-small cell lung cancer.
【Keyword】：Topotecan;DDP;chemotherapy;non-small cell lung cancer;brain metastasis